试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-12
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
编号:NCT04128020登记状态:入组前撤回企业 / 申办者:Sherif Farag
药物 / 成分:Nivolumab、Azacitidine
登记的停止原因(原文):Funder withdrew funding after not accruing any subjects after 1 year.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-12
Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia
编号:NCT04460105登记状态:入组前撤回企业 / 申办者:Shire
药物 / 成分:Lanadelumab、Placebo
登记的停止原因(原文):Study was withdrawn due to challenges in site recruitment and lack of patient enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-09
Manuka Eye Droops for Treatment of Allergy
编号:NCT03862053登记状态:入组前撤回企业 / 申办者:Toyos Clinic
药物 / 成分:Manuka honey
登记的停止原因(原文):not enough time to complete trial;covid
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers
编号:NCT01907594登记状态:入组前撤回企业 / 申办者:New York State Psychiatric Institute
药物 / 成分:D-cycloserine、Nicotine Replacement Therapy (patch)、Smoking Cue Exposure、Progressive Muscle Relaxation
登记的停止原因(原文):Ran out of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Prevention of Thromboembolic Events in Total Knee Replacement Patients
编号:NCT03393481登记状态:入组前撤回企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:MAA868、Enoxaparin
登记的停止原因(原文):Trial cancelled before First Patient First Visit (no patient enrolled)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
编号:NCT03398434登记状态:入组前撤回企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:MAA868、Apixaban
登记的停止原因(原文):Trial cancelled before First Patient First Visit (no patient enrolled)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Insulin Signaling in Skeletal Muscle
编号:NCT03452267登记状态:入组前撤回企业 / 申办者:Wayne State University
药物 / 成分:Metformin、Pioglitazone、Placebo
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Vitamin B12 for Carpal Tunnel Syndrome
编号:NCT03802422登记状态:入组前撤回企业 / 申办者:Tri-Service General Hospital (TSGH)
药物 / 成分:Vitamin B12、Normal saline
登记的停止原因(原文):It is hard to enroll patients due to Covid-19 pandemic.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19
编号:NCT04342156登记状态:入组前撤回企业 / 申办者:Tan Tock Seng Hospital
药物 / 成分:Hydroxychloroquine Sulfate 200 milligram (mg) Tab
登记的停止原因(原文):The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-08
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults
编号:NCT04464460登记状态:入组前撤回企业 / 申办者:Takeda
药物 / 成分:TAK-671、TAK-671 Placebo
登记的停止原因(原文):Business Decision (no enrollment)
查看官方原始记录 ↗